Adapting antibody–invertase fusion protein immunoassays to multiwell plates for infectious disease antibody quantification
Open Access
- 17 October 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Sensors & Diagnostics
- Vol. 5 (1) , 83-93
Abstract
Traditional enzyme-linked immunosorbent assays (ELISAs) rely on horseradish peroxidase (HRP)-conjugated antibodies to generate a colorimetric response proportional to target antibody concentration. However, spectrophotometric quantification requires expensive benchtop equipment, limiting its usability for frequent, population-scale immunity screening. To overcome this barrier, we previously developed LC15, an antibody–invertase fusion protein that catalyzes sucrose-to-glucose conversion in proportion to antibody levels. This fusion protein enabled antibody quantification using handheld glucometers – affordable, widely available devices already integrated with telehealth infrastructure. Unlike commercial ELISAs, which report relative antibody titers, LC15 facilitates absolute antibody quantification (μg mL−1), enhancing applications such as epidemiological monitoring and convalescent plasma dosing. To increase the number of clinical samples processed in a single run of the assay, in this study we transitioned from poly(methyl methacrylate) strips to microwell plates, optimizing pH conditions and reagent concentrations. This adaptation yielded similar sensitivity to the original strip-based assay, but with a 5-fold reduction in reagent consumption and in plasma, as opposed to serum used for the previous study. Using the SARS-CoV-2 receptor binding domain (RBD) as the antigen, we applied LC15 in a 96-well plate format to screen 72 clinical samples in triplicate for anti-RBD antibodies. A blinded comparison with commercial ELISAs demonstrated strong linear correlation (R2 = 0.85) over four orders of magnitude in concentration. By combining accuracy with accessibility, this approach has the potential to facilitate population-level immunity assessments, supporting rapid public health responses in future outbreaks.Keywords
Funding Information
- National Institute of General Medical Sciences (T32GM080189)
- National Science Foundation (2143160)
- School of Medicine, Johns Hopkins University
- Office of the Provost, Johns Hopkins University
- Emerson Collective
This publication has 15 references indexed in Scilit:
- Antibody–Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available GlucometersJournal of the American Chemical Society, 2022
- A serological assay to detect SARS-CoV-2 seroconversion in humansNature Medicine, 2020
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineCellular & Molecular Immunology, 2020
- Comparison of conjugation procedures for the preparation of monoclonal antibody-enzyme conjugatesJournal of Immunological Methods, 1988
- Theoretical analysis of the sensitivity of the solid phase antibody assay (ELISA)Molecular Immunology, 1987
- 3,3′,5,5′-Tetramethylbenzidine as an Ames Test Negative Chromogen for Horse-Radish Peroxidase in Enzyme-ImmunoassayJournal of Immunoassay, 1981
- Properties of the internal invertase of yeast, Saccharomyces cerevisiaeBiochimica et Biophysica Acta (BBA) - Enzymology, 1971
- Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin GImmunochemistry, 1971
- Immunoassay using antigen—enzyme conjugatesFEBS Letters, 1971
- Coupling of enzymes to proteins with glutaraldehydeImmunochemistry, 1969